Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lithium Orotate in Early Alzheimer's Disease (LiO-AD)
NCT07459959Phase 2Not yet recruiting
- Sponsor
- Johns Hopkins University
- Start
- Dec 2026
- Primary completion
- Jun 2029
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Lithium orotate with Matched placebo (2 arms). Primary endpoints: Feasibility (Recruitment, Retention) at 9 weeks, Feasibility (Visit Completion) at 9 weeks and 8 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
lithium orotate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07459959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07459959.